Skip to main content

Advertisement

Log in

ASO Visual Abstract: Systemic Therapy for Resected Pancreatic Adenocarcinoma—How Much Is Enough?

  • ASO Visual Abstract
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Funding

The authors have no grants or financial support to report.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Sameer H. Patel MD.

Ethics declarations

Disclosure

D.S. reports funding from Speakers Bureau (Incyte, Genentech). Institutional funding was received from Amgen, Apexigen, Bristol-Myers Squibb, Celgene, FibroGen, Genentech, Medimmune, Merck, OncoMed, and Rafael.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Turner, K.M., Delman, A.M., Vaysburg, D.M. et al. ASO Visual Abstract: Systemic Therapy for Resected Pancreatic Adenocarcinoma—How Much Is Enough?. Ann Surg Oncol 29, 3475–3476 (2022). https://doi.org/10.1245/s10434-022-11421-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-022-11421-7

Navigation